<?xml version="1.0" encoding="UTF-8"?>
<p id="p0120">However, the limitation of our study shouldn't be neglected. First, the sample size from our study was relatively small because of our strict inclusion criteria. Second, introduced bias of retrospective design was inevitable due to that all factors correlated with efficacy of oseltamivir were unable to be controlled. Because we faced to the newly virus and attempted several courses of antiviral treatments. Currently, a phase III trial and a phase IV trial are underway by Tongji hospital, another affiliated hospital of Huazhong University of Science and Technology to evaluate the safety and efficacy of oseltamivir in patients with COVID-19 (ClinicalTrials.gov Identifier: NCT04255017 and NCT04261270).</p>
